Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 4OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Neuroblastoma 4Ganglioneuroblastoma 4Breast Neoplasms 4Prostatic Neoplasms 3Medulloblastoma 3Wilms Tumor 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Embryonal 2Carcinoma 2Burkitt Lymphoma 2Astrocytoma 2Uterine Cervical Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Seizures 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1

Interventions

Vincristine 6Doxorubicin 5Cyclophosphamide 5merphos 4Specimen Handling 4Radiotherapy 4Prednisone 4Methotrexate 4pegaspargase 3calaspargase pegol 3Prednisolone 3Methylprednisolone 3Hydrocortisone 3Etoposide 3Daunorubicin 3Cytarabine 3Biopsy 3Asparaginase 3exifone 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Thioguanine 2Spinal Puncture 2Mercaptopurine 2Medrol Veriderm 2Magnetic Resonance Spectroscopy 2Filgrastim 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Magnetic Resonance Spectroscopy × Clear all
NCT03504644 2026-05-13

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡